retatrutide dosing clinical trials Reta trial data & — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 for metabolic health — targeting GLP-1, GIP retatrutide clinical trial dosing schedule

Regarding cardiovascular parameters, GLP-1 treatment was associated with a significant reduction in systolic blood pressure (Fig

While GLP-1 medications do not cause thyroid cancer in the general population, anyone with suspicious thyroid findings or uncontrolled thyroid conditions requires specialist clearance

Both are part of a new class of drugs known as GLP-1 receptor agonists, but they have some key differences in how they work and their overall efficacy

2.4 Retinal remodeling Recent discoveries have revealed the remodeling capabilities of GLP-1RAs in the retina

The primary effects of GLP-1 RA involve controlling blood glucose levels in individuals with T2DM by promoting glucose-dependent insulin release [67], inhibiting glucagon production, decreasing hepatic glucose output [68], improving insulin secretion, reducing the apoptosis of -cells, promoting the proliferation of -cells [69] and curbing weight gain [70]

Diabetes 63 , 32213229 (2014)